Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Metastatic Colorectal Cancer

Join Barish Edil, MD, and Wells Messersmith, MD, as they present their multidisciplinary expertise on a range of cases pertaining to Metastatic Colorectal Cancer.

The management of metastatic colorectal cancer (mCRC) involves a continuum of care in which patients are exposed sequentially to a variety of active agents (5-FU/leucovorin, capecitabine, irinotecan, oxaliplatin, bevacizumab, ziv-aflibercept, cetuximab, panitumumab, regorafenib), either in combinations or as single agents. The choice of therapy is based on the goals of treatment (i.e., eradication of micrometastases in resectable patients, tumor shrinkage to obtain resectability, slowing of disease in unresectable patients), the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, and the mutational status of the tumor. For the past several years, patients with tumor mutations in exon 2 of KRAS have not been offered panitumumab or cetuximab because tumors with such mutations are insensitive to these drugs.

In patients with mCRC, clinicians need to consider the goals of therapy (i.e., eradication of micrometastases in resectable patients, tumor shrinkage to obtain resectability, slowing of disease in unresectable patients), the different efficacy and toxicity profiles of the drugs, and patient preferences. Other considerations for the selection of therapy include the previous treatment history and, importantly, the tumor markers of the patient. Molecular testing has played an increasingly critical role for the determination of therapy.

Target Audience

This educational activity is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for the treatment of patients with metastatic colorectal cancer
  • Describe the multidisciplinary aspects of the management of patients with metastatic colorectal cancer
  • Identify the key characteristics of metastatic colorectal cancer that trigger decision points
  • Recognize situations where optimal care may require adapting guidelines recommendations to individual circumstances
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Exelixis Inc.
  • Genentech BioOncology
  • Janssen Biotech, Inc.
  • Novartis Oncology
  • Takeda Oncology

Supported by a grant from Onyx Pharmaceuticals.

Supported by independent educational grants from Merck and Prometheus Laboratories Inc.

Supported by an unrestricted, educational grant from Celgene Corporation.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.81 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
08/26/2014
Course expires: 
08/26/2015
Cost:
$0.00

Barish Edil, MD
University of Colorado Cancer Center

Wells Messersmith, MD
University of Colorado Cancer Center

Available Credit

  • 0.75 Participation
  • 0.81 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Accreditation Period

Course opens: 
08/26/2014
Course expires: 
08/26/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • For Windows: JavaScript and cookies enabled, Active X enabled and unblocked for Microsoft Internet Explorer, Java 6.0 or above
  • For Mac: JavaScript and cookies enabled, Plug-ins enabled in Safari, Java 6.0 or above
  • Adobe Reader or other PDF reader software for certificate viewing/printing